Blood Transfusions in Dogs and Cats Receiving Hemodialysis: 230 Cases (June 1997–September 2012)

C. Langston, A. Cook, A. Eatroff, E. Mitelberg, and S. Chalhoub

Background: Multiple factors exist that contribute to anemia in dogs and cats receiving hemodialysis, can necessitate transfusion.

Objectives: To describe blood product usage in dogs and cats with acute and chronic kidney disease that were treated with intermittent hemodialysis to determine risk factors associated with the requirement for blood product transfusion.

Animals: 83 cats and 147 dogs undergoing renal replacement therapy at the Animal Medical Center for acute or chronic kidney disease.

Methods: Retrospective medical record review of all dogs and cats receiving renal replacement therapy for kidney disease, from June 1997 through September 2012.

Results: Blood products (whole blood, packed RBCs, or stromal-free hemoglobin) were administered to 87% of cats and 32% of dogs. The number of dialysis treatments was associated with the requirement for transfusion in cats (adjusted OR 2.21, 95% CI 1.13, 4.32), but not in dogs (adjusted OR 0.98, 95% CI 0.95, 1.03). Administration of a blood product was associated with a higher likelihood of death in dogs (OR 3.198, 95% CI 1.352, 7.565; P = .0098), but not in cats (OR 1.527, 95% CI 0.5404, 4.317, P = .2).

Conclusions and Clinical Importance: Veterinary hospitals with a hemodialysis unit should have reliable and rapid access to safe blood products in order to meet the needs of dogs and cats receiving dialysis.

Key words: Anemia; Darbepoetin; Erythropoiesis-stimulating agent; Kidney failure; Renal replacement therapy.

Abbreviations:

| Abbreviation | Description |
|--------------|-------------|
| AKI          | acute kidney injury |
| CKD          | chronic kidney disease |
| DA           | darbepoetin alfa |
| ESA          | erythropoiesis-stimulating agent |
| HBOC         | stromal-free hemoglobin |
| rhEPO        | recombinant human erythropoietin |

Hemodialysis is an increasingly used modality for both acute and chronic kidney disease, although availability remains limited to a small number of veterinary hospitals. Comorbidities can complicate treatment in these often-critically ill cats and dogs. Anemia, in particular, occurs commonly and can require administration of blood products.

Multiple factors contribute to anemia in cats and dogs receiving hemodialysis. Both clotting and incomplete return of blood in the extracorporeal circuit during dialysis and hemorrhage secondary to anticoagulant administration can be important sources of blood loss, especially in smaller cats and dogs. Other factors contributing to blood loss include hemorrhage due to uremic thrombocytopenia or gastrointestinal ulceration, and repeated blood sampling. Insufficient erythropoietin production, anemia of inflammatory disease, absolute or functional iron deficiency, decreased red blood cell survival, and hemolysis can also play a role. Administration of exogenous erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa in patients with erythropoietin deficiency can reduce transfusion dependency in people with chronic kidney disease (CKD), and play a role in treating anemia in patients undergoing dialysis for acute kidney injury (AKI).

Although a wealth of information regarding transfusion medicine in dogs and cats is available, to the authors’ knowledge, no published reports exist describing the use of transfusions or the impact of ESA use in cats and dogs receiving hemodialysis. Cats and dogs require transfusion of a substantial volume of blood products for a variety of reasons, both related and unrelated to hemodialysis. The primary objective of this study was to describe blood product usage in dogs and cats with acute and chronic kidney disease that were treated with intermittent hemodialysis. A secondary objective of this study was to determine risk factors associated with the requirement for administration of blood products.

Materials and Methods

Medical records of all cats and dogs undergoing renal replacement therapy at the Animal Medical Center for acute or chronic...
kidney disease during the study period (June 22, 1997–September 31, 2012) were reviewed. Data recorded for each cat or dog included species, age, breed, body weight before the first hemodialysis treatment, PCV before the first hemodialysis treatment, and number of hemodialysis treatments administered. The reason for initiation of renal replacement therapy was classified, according to the chronicity of renal injury, into the following categories: AKI, acute on chronic kidney disease, and CKD. Cats and dogs with acute kidney injury were assigned to this category if there was no previous evidence that they met the criteria for classification in any of the 4 International Renal Interest Society stages for CKD. Cats and dogs were considered to have acute on chronic kidney disease if stable CKD (defined by the International Renal Interest Society staging scheme) was present before an abrupt rise in serum or plasma creatinine concentration. Cats and dogs were considered to have CKD if they were classified in stage IV of the International Renal Interest Society staging scheme either before initiation of renal replacement therapy or during the course of renal replacement therapy. In addition, whether an ESA was administered and, if so, the specific agent used (either rhEPO or DA) was recorded. Both cats and dogs were divided into 2 groups: those that were administered a transfusion of either packed red blood cells (pRBC), whole blood (WB), or a hemoglobin-based oxygen carrier (HBOC), and those that did not administer a blood product with oxygen carrying capacity. Cats and dogs administered frozen plasma or fresh frozen plasma and no other blood product were included in the second group. For the transfusion group, the reason for transfusion, the type of blood product used, and the total amount transfused (in mL) were also recorded. Transfusions that were administered before the patient’s admission to the Animal Medical Center or after the dialysis catheter was removed were not included. Patients were excluded if the medical record was incomplete, if they did not survive the first hemodialysis treatment, or if they only received 1 hemodialysis treatment for intoxication without renal impairment.

When the volume of blood product administered was not specifically documented in the medical record, the volume was estimated based on a per unit basis. A unit of canine pRBC was estimated at 150 mL, and ½ unit of canine pRBC was estimated at 75 mL. One unit of canine WB was estimated at 400 mL, and ½ unit of canine WB was estimated at 200 mL. Similarly, 1 unit of feline pRBC was estimated at 30 mL and ½ unit of feline pRBC was estimated at 15 mL. One unit of feline WB was estimated at 150 mL, and ½ unit of feline WB was estimated at 75 mL. To calculate the total amount of blood product used, we considered each mL of WB or HBOC to be equal to 0.5 mL of pRBC.

Survival was defined as renal recovery sufficient to live independently of dialysis for at least 30 days. Animals that died or were euthanized during hospitalization or within 30 days of the final dialysis treatment were placed in the nonsurvival category. Only cats and dogs with AKI and acute on chronic kidney disease were included in survival analysis because it was assumed that those with CKD were indefinitely dependent on renal replacement therapy for survival.

Data were analyzed by a statistical software package (Stata 12.0 for Windows, Stata Corporation, College Station, TX). All continuous variables were graphically inspected for a normal distribution. Because most continuous variables had a non-normal distribution, median, IQR, and range were used to describe and the Mann-Whitney U-tests was used to compare the distributions of predialysis variables and the number of dialysis treatments between transfused and nontransfused cats and dogs. Categorical variables were expressed as frequencies and percentages, and chi-square or Fisher’s exact tests were used to compare these variables between transfused or nontransfused cats and dogs. Univariate and multivariate logistic regression analysis was used to determine if age, weight, predialysis PCV, reason for renal replacement therapy, or the number of dialysis treatments predicted the requirement for transfusion. All statistical significance was set at \( \alpha = 0.05 \).

**Results**

During the study period, 92 cats and 171 dogs were treated with a variety of forms of renal replacement therapy (RRT). Three cats and 2 dogs were excluded because they did not survive the first hemodialysis treatment. Five cats and 10 dogs were excluded due to incomplete medical records. One cat and 12 dogs were treated with renal replacement therapy once for acute intoxication without renal impairment and thus excluded from analysis. The remaining 230 animals (83 cats and 147 dogs) were included in the study.

**Cats**

Of the 83 cats included in analysis, 5 cats (6%) were treated with RRT on 2 separate occasions each (9 months to 13 years apart). For statistical purposes, the second episode for each of these cats was excluded from analysis. Four of these 5 cats were administered blood products during the first episode of renal replacement therapy, and all 5 of these cats were administered blood products during the second episode.

Blood products were administered to 72 of the 83 cats (87%) during the course of renal replacement therapy. Variables for all cats before dialysis included in the analysis are presented in Table 1. The only variable before dialysis for which a statistically significant difference was demonstrated between transfused and nontransfused cats was PCV. The reason for initiation of renal replacement therapy is described in Table 2. The median number of dialysis treatments administered to transfused cats was significantly different from the median number of dialysis treatments administered to nontransfused cats (4 vs. 2, \( P = 0.0022 \); Fig 1).

The volume of blood products administered is reported in Table 3. Twenty-six cats received more than 1 blood product, 20 cats received only WB, 22 received only pRBC, and 2 received only HBOC. By converting each mL of WB or HBOC to 0.5 mL pRBC, we were able to estimate the total volume of blood product used (Table 3). The volume of the blood units was available in the medical record of 25 cats and estimated for 19 cats. Thirteen cats received blood products at the initiation of extracorporeal circulation in 27 treatments.

Of the 83 cats in the study, ESA was administered to 28 (34%) cats. rhEPO was administered in 10 cats (until mid-2007), while DA was administered in 18 cats (after mid-2007). All cats receiving an ESA were in the transfusion group. While both the PCV before dialysis and the number of dialysis treatments were associated with the requirement for transfusion in univariate analysis, only the number of dialysis treatments was independently associated with the requirement for transfusion (Table 4). For chronicity of
kidney disease, the presence of CKD was omitted from the model because all 11 cats with CKD were administered at least 1 blood transfusion (Table 4).

Of the 61 cats with AKI or acute on chronic kidney disease that were administered transfusion, 28 (46%) were classified as survivors (11 cats with AKI and 17 cats with acute on chronic kidney disease). Two of these 28 cats subsequently received a renal transplant (and survived for greater than 30 days). Thirty-three cats (54%) of the transfused cats with AKI (15 cats) or acute on chronic kidney disease (18 cats) were classified as non-survivors. One of these cats received a renal transplant, but died within 30 days of the final dialysis treatment. An association between transfusion and survival was not demonstrated ($P = .2$).

### Dogs

Of the 147 dogs included in the analysis, 2 dogs were treated with hemodialysis on 2 occasions (1–4.5 years apart). For statistical purposes, the second episode for each of these dogs was excluded from analysis. Neither of these dogs were administered blood products during the first episode of renal replacement therapy, but both dogs were administered blood products during the second episode. Blood products were administered to 47 of the 147 dogs (32%) during the course of renal replacement therapy. Predialysis variables for all dogs included in the analysis are presented in Table 5. The only variable for which a statistically significant difference was demonstrated between transfused and nontransfused dogs was PCV. The reason for initiation of renal replacement therapy is described in Table 6. A difference in the number of dialysis treatments administered

### Table 1. Comparison of age, weight, predialysis PCV, and sex of transfused and nontransfused cats.

|                      | All Cats | Transfused Cats | Nontransfused Cats | $P$ Value |
|----------------------|----------|-----------------|--------------------|-----------|
| **Age (years)**      | 8.2      | 8.4             | 7.5                | .29       |
| IQR                  | 5.3, 11.1| 5.4, 11.7       | 3.6, 9.7           |           |
| Range                | 0.6, 15.9| 1.0, 15.9       | 0.6, 13.0          |           |
| **Weight (kg)**      | 4.9      | 4.8             | 5.0                | .41       |
| IQR                  | 3.9, 6.0 | 3.9, 6.0        | 4.1, 6.1           |           |
| Range                | 2.3, 12.1| 2.3, 8.8        | 3.3, 12.1          |           |
| **PCV (%)**          | 23       | 22.5            | 29                 | .02*      |
| IQR                  | 20, 30   | 19, 29.5        | 25, 30             |           |
| Range                | 12, 38   | 12, 38          | 20, 34             |           |
| **Sex (# cats)**     |          |                 |                    |           |
| F                    | 33       | 50             | 27                 | .33       |
| M                    |          |                 |                    |           |

Data presented as mean ± standard deviation for age, weight, and PCV.

*Statistically significant.

### Table 2. Reason for initiation of renal replacement therapy in cats.

|                      | All Cats | Transfused Cats | Nontransfused Cats |
|----------------------|----------|-----------------|--------------------|
| **Acute kidney injury (# cats)** | 30       | 26              | 4                  |
| **Acute on chronic kidney disease (# cats)** | 42       | 35              | 7                  |
| **Chronic kidney disease (# cats)** | 11       | 11              | 0                  |
| **Total (# cats)**    | 83       | 71              | 11                 |

### Table 3. Volume of blood products administered to cats and dogs receiving hemodialysis.

|                      | pRBC | WB | HBOC | Total Blood Product |
|----------------------|------|----|------|---------------------|
| **Cats**             |      |    |      |                     |
| N                    | 42   | 44 | 14   | 72                  |
| Total volume (ml)    | 70.5 | 61.5| 60   | 62                  |
| IQR                  | 30, 106| 43, 100| 22, 95| 35, 105.5            |
| Range                | 15, 413| 21, 432| 10, 115| 10.5, 413            |
| Volume/kg body wt    | 13.2 | 13.6| 12.7 | 15                  |
| IQR                  | 7.3, 31.1| 836, 23| 5.6, 16.6| 7, 24.6              |
| Range                | 3, 79 | 5.1, 52.7| 1.5, 41.3| 2.8, 79.3            |
| Dogs                 |      |    |      |                     |
| N                    | 44 (94%) | 7 | 5   | 47                  |
| Total volume (ml)    | 260  | 350| 250  | 250                 |
| IQR                  | 117.5, 475| 140, 450| 155, 375| 135, 530             |
| Range                | 30, 1810| 120, 450| 125, 500| 30, 1810             |
| Volume/kg body wt    | 16.9 | 17.7| 8.1  | 17.2                |
| IQR                  | 10.9, 27| 10, 20| 6, 18.1| 9.4, 27.7            |
| Range                | 0.6, 63.6| 9.7, 22| 4.9, 19.1| 0.6, 63.6            |

Fig 1. Comparison of number of dialysis treatments based on transfusion status.

---

404 Langston et al
of blood products administered is reported in Table 3. Some dogs might have received more than 1 product type. By means of the same conversion factor described previously, we were able to estimate the total volume of blood product used per dog (Table 3). The volume of the blood units was available in the medical record of 33 dogs and estimated for 13 dogs. Only the predialysis PCV was associated with the requirement for transfusion in both the univariable and multivariable analyses (Table 7).

An ESA was administered in 37 dogs (25%). Of these 37 dogs, rhEPO was administered in 15 (41%) dogs (before and during 2004), while DA was administered in 22 (59%) dogs (from 2004 and later). Twelve dogs receiving an ESA (32%) were in the transfusion group. Conversely, 25 dogs receiving an ESA (68% of dogs receiving an ESA) were in the nontransfusion group. An association between administration of an ESA and administration of a blood product could not be demonstrated \( (P = 1) \). Of all the dogs included in the study, 72 (49%) received a blood replacement product, an ESA, or both.

Of the 40 dogs with AKI or acute on chronic kidney disease that were administered transfusion, 9 (23%) were classified as survivors (7 dogs with AKI and 2 dogs with acute on chronic kidney disease). Thirty-one (78%) of the transfused dogs with AKI (28 dogs) or acute on chronic kidney disease (3 dogs) were classified as nonsurvivors. Of the 82 dogs with AKI (72 dogs) or acute on chronic kidney disease (10 dogs) that were not administered a transfusion, 39 (48%) dogs survived (38 dogs with AKI and 1 dog with acute on chronic kidney disease). One of the nontransfused dogs was lost to follow-up. The median PCV before the first dialysis treatment was 30% in survivors and nonsurvivors. Administration of a blood product was associated with a higher likelihood of mortality \( (OR 3.198, 95\% CI 1.352, 7.565; P = .0098) \).

Discussion

Many veterinary hospitals rely on both commercial acquisition of blood products and maintenance of a blood donor program to sustain an adequate supply of feline and canine blood products. Therefore, the introduction of any new treatment modality, such as hemodialysis, that may increase the use of blood products, should be performed with consideration and proper planning for adequate availability of red blood cell products. The information obtained from this study will be useful for any veterinary hospital planning to initiate a hemodialysis program, as this study demonstrates that, in our hospital, a large proportion of cats (87%) and a moderate proportion of dogs (32%) treated with intermittent hemodialysis are administered blood products.

There are several possible explanations for the frequent requirement for blood product transfusions in veterinary hemodialysis patients. It is suspected, although not proven, that blood loss is a large contributor to anemia and the need for transfusion. At the conclusion of each dialysis treatment, the blood in the
extracorporeal circuit is returned to the patient; however, blood that has clotted or remains in gravity-dependent portions of the extracorporeal circuit cannot be returned. There is wide variation in the amount of blood that remains in the dialyzer, with 1 report of an average of 2.05\(\pm\)3.21 mL of packed RBC per dialyzer (range, 0.01–24 mL) used in people. 10 That study found polyacrylonitrile (AN69) dialyzers demonstrating more blood loss than cellulose acetate. In cats, the extracorporeal circuit volume, which includes the tubing and the dialyzer, averages 23% of the blood volume of the patient, ranging from 7 to 50% in our unit. In dogs, the extracorporeal circuit volume, which includes the tubing and the dialyzer, averages 9% of the blood volume, ranging from 2 to 35%. Thus, even if the volume of blood left in the circuit is a small fraction of the circuit size, the cumulative loss in cats can become clinically relevant. Interestingly, the subjective scoring of the amount of clotting in dialyzers used in cats is typically less than the score for dogs. 11,12

Catastrophic intradialytic events such as circuit clotting or inadvertent catheter removal can occur, preventing either partial or complete extracorporeal circuit blood return and further contributing to blood loss. Complete loss of the blood in the circuit occurs in less than 1% of all treatments in our unit.

There are many additional potential sources of blood loss in the cat or dog with AKI. Uremic thrombocytopenia likely contributed to clinically apparent bleeding in some patients. Coagulation disorders associated with leptospirosis, the etiologic agent of AKI in a significant part of our canine dialysis population, were also a contributor to bleeding disorder. Sources of bleeding identified during therapy were causes commonly encountered in veterinary medicine, including intraoperative bleeding and gastrointestinal bleeding.13-17 The 3 cats with retroperitoneal or perirenal hemorrhage all had ureteral obstruction. Systemic heparin anticoagulation was used in the vast majority of dialysis treatments reported here to prevent clotting in the extracorporeal circuit, with a target of prolonging the activated clotting time to 1.5–2 times normal. Although the anticoagulation should be of limited duration based on heparin’s relatively short half-life (1–2 hours in people), it can induce or exacerbate bleeding.

Hemolysis can occur in conjunction with hemodialysis, precipitated by contaminants in the water supply, hypotonic or overheated dialysate, or extracorporeal circuit tubing problems (kinked or manufacturing defects).18-20 Excessive negative access pressure (less than –350 mmHg) has been reported to cause minor hemolysis.20,21 Careful attention to access pressure makes this unlikely in our unit. Subjectively, hemolyzed postdialysis samples were uncommon in the absence of transfusion.

In some treatments, blood transfusions were administered during initiation of a hemodialysis treatment to compensate for large volumes of blood being removed from the patient to fill the extracorporeal circuit. The transfusion was initiated by priming the extracorporeal circuit with a blood product, rather than with saline or a synthetic colloid. Using blood to prime the extracorporeal circuit is a common practice in pediatric CRRT.22 An alternate method is a rapid transfusion directly to the patient as the extracorporeal circulation is started. Despite concerns about rapid transfusion (typically in less than 15 minutes), we have only observed 1 cat with clinical signs that may have been associated with a minor transfusion reaction. That cat had transient (15 minutes) facial pruritus at the start of

### Table 6. Reason for initiation of renal replacement therapy in dogs.

|                      | All Dogs | Transfused Dogs | Nontransfused Dogs |
|----------------------|----------|-----------------|--------------------|
| Acute kidney injury  | 107      | 35              | 72                 |
| Acute on chronic     | 15       | 5               | 10                 |
| Chronic kidney disease | 25     | 7               | 18                 |
| Total (# dogs)       | 147      | 47              | 100                |

### Table 7. Univariate and multivariate logistic regression analyses for risk factors associated with the requirement for blood transfusion in dogs.

| Variable              | Univariate Analysis | Multivariate Analysis |
|-----------------------|---------------------|-----------------------|
|                      | Odds Ratio | 95% CI   | P Value | Odds Ratio | 95% CI   | P Value |
| Age (years)           | 0.93       | 0.85, 1.03 | .15     | 0.92       | 0.83, 1.02 | .098 |
| Weight (kg)           | 0.98       | 0.95, 1.01 | .13     | 0.98       | 0.96, 1.01 | .22  |
| PCV (%)               | 0.94       | 0.88, 0.99 | .025*   | 0.94       | 0.88, 0.99 | .030* |
| # of dialysis treatments | 0.98     | 0.94, 1.02 | .31     | 0.98       | 0.95, 1.03 | .50  |
| Etiology              | Referent   | Referent    |         | Referent   | Referent    |         |
| AKI                   |             |             |         | 1.19       | 0.38, 3.77  | .77   |
| AoCKD                 |             |             |         | 1.29       | 0.37, 4.49  | .69   |
| CKD                   | 0.844      | 0.32, 2.20  | .73     | 0.92       | 0.32, 2.72  | .89   |

*Statistically significant.
dialysis, which resolved without intervention. Blood
priming increases the cost of providing dialysis, due to
the cost of blood products and cross-matching, but sub-
jectively, hemodynamic stability seems better during
treatments initiated with a blood prime in cats.

In the majority of situations, it was impossible to
determine a precise reason a transfusion was adminis-
tered. In the earlier years of the study period, limita-
tions in available blood supply may have impacted
decisions to transfuse, particularly in cats, whereas
a canine blood product was generally readily available.
Despite a normal PCV before the first dialysis treatment
in some animals, development of anemia over the
course of hospitalization was common. In some ani-
mals, a defining event triggering transfusion such as se-
vere blood loss was present, although not all animals
with identifiable major blood loss received a transfu-
son. The decision to administer a transfusion was based
on clinical assessment. 9,23 Disturbances of suffi-
cient oxygen delivery to the tissues from hypotension,
respiratory dysfunction related to volume overload or
pulmonary edema, or anemia were common with
administration of HBOC. The predominant product used
in dogs was pRBC. In cats, we specifically wanted only pRBC due to volume
overload. In dogs, pRBC was the predominant product
available during the entire study period and was the
predominant product used.

Stromal-free hemoglobin was used when blood supply
was limited or a compatible donor could not be found.
Use of these products and complications associated
with them have been described in both dogs and cats.24–26
Despite potential complications associated with use, HBOCs increase oxygen delivery to tissues
when perfusion is maintained. 25 HBOC is no longer
available in the USA.

Two thirds of the transfused cats and 2/3 of transfused
dogs had some chronic component to their disease, but
only 11 cats and 7 dogs in the transfused groups had
end-stage renal disease. The majority of cats with an
acute exacerbation of CKD had ureteral obstruction.
Most had no clinical evidence of uremic signs before an
acute obstruction and would not likely have been ane-
mic if baseline values had been available. Chronic ery-
thropoietin deficiency seems unlikely to have played
a role in the pathogenesis of anemia in this population.
However, AKI can abruptly decrease erythropoietin
production, and critical illness with AKI is associated
with resistance to the effects of endogenous erythropoi-
etin, making it difficult to replenish lost or damaged red
blood cells. 14,27

The use of ESA is common in people receiving
hemodialysis for CKD. The introduction of ESA has
dramatically decreased, but not eliminated, the adminis-
tration of blood transfusions in this population. 9 In
more recent years, ESAs have been investigated in treat-
ment of AKI. Although critical illness blunts the
responsiveness to endogenous erythropoietin, these
patients remain responsive to exogenous ESA. 27–29
Additionally, ESAs have anti-apoptotic effects and have
shown renoprotective effects in some, but not all studies. 28,30,31
Darbepoetin was used almost exclusively from mid-2004, and the use of ESA has increased. We
were unable to demonstrate that cats and dogs receiving
ESA were less likely to be transfused. Our criteria for
administering an ESA were not standardized. It is prob-
able that multiple prior transfusions influenced the deci-
sion to start ESA use in cats. Starting ESA earlier in the
course of dialysis might decrease transfusion
requirements.

There was no difference in survival in transfused cats
(46%) compared to nontransfused cats (64%) in the
cats with AKI or acute on chronic disease, but few cats
in the study did not receive a transfusion. Retrospective
studies in transfused cats with various disease processes
have reported 59–64% survival. 16,17,32,33 Transfused
dogs were 3 times more likely to die. The survival rate
of 23% in this transfused group is much lower than
reported survival to discharge from the hospital of 47–
61% in transfused dogs with AKI or acute on chronic disease processes. 34,35 Liberal transfusion may increase mortality
compared to restrictive transfusion strategies. 36
Although numerous studies have found higher mortality
rates in people receiving more transfusions, a recent
review found that while restrictive transfusion strategies
reduce in-hospital deaths, they do not reduce 30-day
case fatality in people. 37 An alternative explanation is that this
association is not a causal relationship and that dogs
that need a transfusion have more severe disease or are
less responsive to ESA administration. While transfu-
sion appears to be an integral part of dialytic therapy
in cats, the need for transfusion in a dog indicates a worse
prognosis.

There was an independent association of the number
of dialysis treatments with the likelihood of transfusion
in cats, in that each dialysis treatment doubled the
chance a cat would receive a transfusion. This associa-
tion was not present in dogs. The greater the number of
treatments administered, more cumulative blood loss in
the extracorporeal circuit is expected, leading to an
increase in transfusion requirements in cats. Larger
dogs would be more likely to tolerate multiple episodes
of blood loss associated with multiple treatments with-
out requiring a transfusion.

A major limitation is the retrospective nature of the
study. Oftentimes, the contribution of blood loss via
gastrointestinal hemorrhage or other sources of bleeding
was speculative. A necropsy was not performed on all
cases. Furthermore, the volume of blood product trans-
fused on a mL/kg basis can be altered by the volume
status of the patient. Hemodialysis patients often pre-
sent with clinically significant volume overload and
although dialysis can remove excess fluid by the process
of ultrafiltration, hemodynamic instability in the
patients may necessitate a slow removal process as sev-
eral dialysis treatments performed over several days.
The risk of exacerbating volume overload is always bal-
anced against the need for oxygen carrying capacity,
and might have limited the amount of blood products
used in an individual cat or dog in the early stages of dialysis therapy. Another limitation is that the transfusion practices of our unit might not represent transfusion practices in other practices.

Conclusion

Dogs and cats undergoing hemodialysis often require administration of a blood product. In this population, over 50% required a blood product of some type. The need for transfusion might be directly related to hemodialysis or the underlying disease process but is most often multifactorial. Veterinary hospitals with a hemodialysis unit should have reliable and rapid access to safe blood products in order to meet the needs of the dialysis patients. Further study is warranted to determine whether administration of erythropoiesis-stimulating agents make a substantial impact on blood product administration in this population.

Footnotes

a Oxyglobin, OPK Biotech, Cambridge, MA
b Epogen, Amgen, Thousand Oaks, CA
c Procrit, Centocor Ortho Biotech Products, Horsham, PA
d Aranesp, Amgen, Thousand Oaks, CA

Acknowledgments

Conflict of Interest Declaration: Authors declare no conflict of interest.

Off-label Antimicrobial Declaration: Authors declare no off-label use of antimicrobials.

References

1. Langston CE, Cowgill LD, Spano JA. Applications and outcome of hemodialysis in cats: A review of 29 cases. J Vet Intern Med 1997;11:348–355.
2. Fischer JR, Pantaleo V, Franeey T, et al. Veterinary hemodialysis: Advances in management and technology. Vet Clin North Am Small Anim Pract 2004;34:935–967, vi–vii.
3. Harris CL, Krawiec DR. The pathophysiology of uremic bleeding. Compendium Continuing Educ Practicing Vet 1990;12:1294–1298.
4. Thavendiranathan P, Bagai A, Ebdida A, et al. Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. J Gen Intern Med 2005;20:520–524.
5. Ibrahim HN, Ishani A, Foley RN, et al. Temporal trends in red blood tranfusion among US dialysis patients, 1992-2005. Am J Kidney Dis 2008;52:1115–1121.
6. Cowgill LD, James KM, Levy JK, et al. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. J Am Vet Med Assoc 1998;212:521–528.
7. Langston CE, Reine NJ, Kittrell D. The use of erythropoietin. Vet Clin North Am Small Anim Pract 2003;33:1245–1260.
8. Callan MB, Rentko VT. Clinical application of a hemoglobin-based oxygen-carrying solution. Vet Clin North Am Small Anim Pract 2003;33:1277–1293, vi.
9. Prittie JE, Administration of biological products In: Burkitt Creedon JM, Davis H, eds. Advanced Monitoring and Procedures for Small Animal Emergency and Critical Care. Ames, Iowa: Wiley Blackwell, 2012:759–775.
10. Kalocheritis P, Vlamis I, Belesi C, et al. Residual blood loss in single use dialyzers: Effect of different membranes and flux. Int J Artif Organs 2006;29:286–292.
11. Kerl ME, Langston CE, Cohn LA. Anticoagulation with unfractionated heparin during hemodialysis in dogs (abstract). J Vet Intern Med 2005;19:433–434.
12. Langston CE, Cohn LA, Kerl ME. Anticoagulation with unfractionated heparin during hemodialysis in cats (abstract). J Vet Intern Med 2005;19:434.
13. Patel NS, Collino M, Yaqoob MM, et al. Erythropoietin in the intensive care unit: Beyond treatment of anemia. Ann Intensive Care 2011;1:40.
14. Liangos O, Pereira BJ, Jaber BL. Anemia in acute renal failure: Role for erythropoiesis-stimulating proteins? Artif Organs 2003;27:786–791.
15. Barfield D, Adamantos S. Feline blood transfusions: A pinker shade of pale. J Feline Med Surg 2011;13:11–23.
16. Roux FA, Deschamps YJ, Blais MC, et al. Multiple red cell transfusions in 27 cats (2003–2006): Indications, complications and outcomes. J Feline Med Surg 2008;10:213–218.
17. Klasar DA, Reine NJ, Hohenhaus AE. Red cell blood transfusions in cats: 126 cases (1999). J Am Vet Med Assoc 2005;226:920–923.
18. Harman E, Dutka P. Hemolyis: A hidden danger. Nephrol Nurs J 2007;34:219–220, 223.
19. Murcutt G. Guarding against hidden haemolysis during dialysis: An overview. Summary of the EDTNA/ERCA Journal Club discussion Spring 2007. J Ren Care 2007;33:191–195.
20. Liangos O, Pereira BJG, Jaber BL. Acute Complications Associated with Hemodialysis. In: Pereira BJG, Sayegh MH, Blake P, eds. Chronic Kidney Disease, Dialysis, & Transplantation, 2nd ed. Philadelphia: Elsevier Saunders, 2005:451–471.
21. Twardowski ZJ. Safety of high venous and arterial line pressures during hemodialysis. Semin Dial 2000;13:336–337.
22. Eding DM, Jelsma LR, Metz CJ, et al. Innovative techniques to decrease blood exposure and minimize interruptions in pediatric continuous renal replacement therapy. Crit Care Nurse 2011;31:64–71.
23. Walley KR. Use of central venous oxygen saturation to guide therapy. Am J Respir Crit Care Med 2011;184:514–520.
24. Gibson GR, Callan MB, Hoffman V, et al. Use of a hemoglobin-based oxygen-carrying solution in cats: 72 cases (1998–2000). J Am Vet Med Assoc 2002;221:96–102.
25. Muir WW, Wellman ML. Hemoglobin solutions and tissue oxygenation. J Vet Intern Med 2003;17:127–135.
26. Weingart C, Kohn B. Clinical use of a haemoglobin-based oxygen carrying solution (Oxyglobin) in 48 cats (2002-2006). J Feline Med Surg 2008;10:431–438.
27. Prakash D. Anemia in the ICU: Anemia of chronic disease versus anemia of acute illness. Crit Care Clin 2012;28:333–343, v.
28. Song YR, Lee T, You SJ, et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: A pilot study. Am J Nephrol 2009;30:253–260.
29. Corwin H, Gettinger A, Rodriguez R, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit Care Med 1999;27:2346–2350.
30. Patel NSA, Sharples EJ, Cuzzocrea S, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 2004;66:983–989.
31. Endre ZH, Walker RJ, Pickering JW, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010;77:1020–1030.
32. Castellanos I, Couto CG, Gray TL. Clinical use of blood products in cats: A retrospective study (1997–2000). J Vet Intern Med 2004;18:529–532.
33. Weingart C, Giger U, Kohn B. Whole blood transfusions in 91 cats: A clinical evaluation. J Feline Med Surg 2004;6:139–148.
34. Callan MB, Oakley DA, Shofer FS, et al. Canine red blood cell transfusion practice. J Am Anim Hosp Assoc 1996;32:303–311.
35. Kerl ME, Hohenhaus AE. Packed red blood cell transfusions in dogs: 131 cases (1989). J Am Vet Med Assoc 1993;202:1495–1499.
36. Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: A meta-analysis and systematic review. Am J Med 2014;127:124–131 e123.
37. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012;4:CD002042.